Yttrium-90 microsphere ablation has been FDA approved for hepatocellular carcinoma for almost 10 years, and has an average survival rate of
13 months , with earlier disease surviving as long as 2 years. It is now being used in selective cases of colon cancer metastatic to the liver.
Surgery is still the mainstay of treatment for hepatocellular carcinoma.